Drug or technology

Gemcitabine

3 developments in the corpus

Following this puts new work involving it at the top of your briefing, with a note saying why it is there. Links are taken from the source record, never inferred.

Latest

Everything in the corpus, newest first.

SEP 8, 2026 · PHASE 3 TRIAL

ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer

ClinicalTrials.gov

This is a clinical trial registry record describing a Phase 3 RCT that is currently recruiting with no results posted; the study design is rigorous but outcomes are not yet available.

PreliminaryPumitamig Nab-paclitaxel/Paclitaxel Breast Neoplasms

Reported

Planned sample size558

PhasePHASE 3

Primary endpoint 1Progression-Free Survival (PFS) as Assessed…

AUG 20, 2026 · PHASE 2 TRIAL

Phase II Trial of Trilaciclib, Pembrolizumab, Gemcitabine and Carboplatin in Metastatic Triple-Negative Breast Cancer

ClinicalTrials.gov

Phase 2 trial with estimated enrollment of 36 participants testing a four-drug combination; no results are reported in this registry record.

PreliminaryNCT06027268 Gemcitabine Wake Forest University Health Sciences

Reported

PhasePhase 2

Planned enrollment36

Primary outcome measureObjective Response at 6 months (initiation…

AUG 4, 2026 · PHASE 1 TRIAL

Gemcitabine, Carboplatin, and Lenalidomide for Treatment of Advanced/Metastatic Urothelial Cancer and Other Solid Tumors

ClinicalTrials.gov

Phase 1 dose-escalation trial with completed enrollment but no efficacy or safety results reported in this registry record; evidence of tolerability and MTD cannot be assessed without posted outcomes.

PreliminaryCancer of the Urethra Urethral Cancer National Cancer Institute (NCI)

Reported

Planned enrollment18

Trial phasePhase 1

Primary outcome measure 1dose limiting toxicity (DLT)